A new diagnostic approach for the initial diagnosis of clinically significant prostate cancer through the addition of PSMA-PET
PRIME Study
Objective of the study
The PRIME study is investigating a new diagnostic approach for prostate cancer to detect clinically significant tumors requiring treatment earlier and more accurately, and to avoid unnecessary biopsies in the future. Currently, when PSA levels (a blood marker for prostate changes) are elevated and multiparametric MRI (mpMRI) results are abnormal, diagnosis is often made via biopsy. This is an invasive procedure and can be associated with pain, infections, and psychological stress.
The study is therefore investigating whether the addition of PSMA-PET/CT (a specialized nuclear medicine imaging technique for visualizing prostate cancer cells) improves diagnostic accuracy. The goal is to effectively complement mpMRI and reduce the number of necessary biopsies. Additionally, artificial intelligence methods are being used to improve image analysis and analyze tumor characteristics more precisely.
